The Impact of FDA’s Draft Guidance for Oncology Patient-Reported Outcomes

Signant’s in-house experts discuss the key takeaways from the FDA’s recent PRO guidance, including the recommended measures and frequency in administration. Readers will also learn the core domains that the agency values the most when reviewing oncology PROM data.